Silencing or stimulation? siRNA delivery and the immune system - PubMed

Review

Silencing or stimulation? siRNA delivery and the immune system

Kathryn A Whitehead et al. Annu Rev Chem Biomol Eng. 2011.

Abstract

Since its inception more than a decade ago, the field of short interfering RNA (siRNA) therapeutics has demonstrated potential in the treatment of a wide variety of diseases. The power behind RNA interference (RNAi) therapy lies in its ability to specifically silence target genes of interest. As more biological data have become available, it has become evident that, in addition to mediating RNAi, siRNA molecules have the potential to potently induce the innate immune system. One of the significant challenges facing the field today is the differentiation between therapeutic effects caused by target-specific, RNAi-mediated gene silencing and those caused by nonspecific stimulation of the innate immune system. Unless appropriate experimental measures are taken to control for RNA-induced immunostimulation, genetic manipulation can be confused with immune activation. This review attempts to provide an accessible background in siRNA-relevant immunology and to highlight the ways in which siRNA can be engineered to avoid or provoke an innate immune response.

Similar articles

• Recent advances in small interfering RNA sensing by the immune system.

  Sioud M. Sioud M. N Biotechnol. 2010 Jul 31;27(3):236-42. doi: 10.1016/j.nbt.2010.02.015. Epub 2010 Feb 26. N Biotechnol. 2010. PMID: 20219711 Review.

• Advances in RNA sensing by the immune system: separation of siRNA unwanted effects from RNA interference.

  Sioud M. Sioud M. Methods Mol Biol. 2010;629:33-52. doi: 10.1007/978-1-60761-657-3_3. Methods Mol Biol. 2010. PMID: 20387141

• Impact of delivery systems on siRNA immune activation and RNA interference.

  Forsbach A, Müller C, Montino C, Kritzler A, Curdt R, Benahmed A, Jurk M, Vollmer J. Forsbach A, et al. Immunol Lett. 2012 Jan 30;141(2):169-80. doi: 10.1016/j.imlet.2011.10.001. Epub 2011 Oct 6. Immunol Lett. 2012. PMID: 22001011

• Staying on message: design principles for controlling nonspecific responses to siRNA.

  Samuel-Abraham S, Leonard JN. Samuel-Abraham S, et al. FEBS J. 2010 Dec;277(23):4828-36. doi: 10.1111/j.1742-4658.2010.07905.x. FEBS J. 2010. PMID: 21078117 Review.

• Astrocytes are very sensitive to develop innate immune responses to lipid-carried short interfering RNA.

  Gorina R, Santalucia T, Petegnief V, Ejarque-Ortiz A, Saura J, Planas AM. Gorina R, et al. Glia. 2009 Jan 1;57(1):93-107. doi: 10.1002/glia.20738. Glia. 2009. PMID: 18709661

Cited by

• Aptamer-guided targeting of the intracellular long-noncoding RNA HOTAIR.

  Wang YL, Chang LC, Chen KB, Wang SC. Wang YL, et al. Am J Cancer Res. 2021 Mar 1;11(3):945-954. eCollection 2021. Am J Cancer Res. 2021. PMID: 33791165 Free PMC article.

• Bunyamwera orthobunyavirus glycoprotein precursor is processed by cellular signal peptidase and signal peptide peptidase.

  Shi X, Botting CH, Li P, Niglas M, Brennan B, Shirran SL, Szemiel AM, Elliott RM. Shi X, et al. Proc Natl Acad Sci U S A. 2016 Aug 2;113(31):8825-30. doi: 10.1073/pnas.1603364113. Epub 2016 Jul 20. Proc Natl Acad Sci U S A. 2016. PMID: 27439867 Free PMC article.

• miR-142: A Master Regulator in Hematological Malignancies and Therapeutic Opportunities.

  Huang W, Paul D, Calin GA, Bayraktar R. Huang W, et al. Cells. 2023 Dec 30;13(1):84. doi: 10.3390/cells13010084. Cells. 2023. PMID: 38201290 Free PMC article. Review.

• Lessons from SARS and MERS remind us of the possible therapeutic effects of implementing a siRNA strategy to target COVID-19: Shoot the messenger!

  Habtemariam S, Berindan-Neagoe I, Cismaru CA, Schaafsma D, Nabavi SF, Ghavami S, Banach M, Nabavi SM. Habtemariam S, et al. J Cell Mol Med. 2020 Sep;24(17):10267-10269. doi: 10.1111/jcmm.15652. Epub 2020 Jul 17. J Cell Mol Med. 2020. PMID: 32677763 Free PMC article. No abstract available.

• Gelofusine Attenuates Tubulointerstitial Injury Induced by cRGD-Conjugated siRNA by Regulating the TLR3 Signaling Pathway.

  Cen B, Liao W, Wang Z, Gao L, Wei Y, Huang W, He S, Wang W, Liu X, Pan X, Ji A. Cen B, et al. Mol Ther Nucleic Acids. 2018 Jun 1;11:300-311. doi: 10.1016/j.omtn.2018.03.006. Epub 2018 Mar 14. Mol Ther Nucleic Acids. 2018. PMID: 29858065 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Ingenta plc

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information

• Research Materials

  • NCI CPTC Antibody Characterization Program